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Summary 
Dendritic cells comprise a system of highly efficient antigen-presenting cells involved in the initiation 
of T cell responses. Herein, we investigated the role of the CD28 pathway during alloreactive 
T cell proliferation induced by dendritic-Langerhans cells (D-Lc) generated by culturing human 
cord blood CD34 § progenitor cells with granulocyte/macrophage colony-stimulating factor and 
tumor necrosis factor or. In addition to expressing CD80 (B7/BB1), a subset of D-Lc expressed 
B70/B7-2. Binding of the CTLA4-Ig fusion protein was completely inhibited by a combination 
of monoclonal antibodies (mAbs) against CD80 and B70/B7-2, indicating the absence of expression 
of a third ligand for CD28/CTLA-4. It is interesting to note that mAbs against CD86 completely 
prevented the binding of CTLA4-Ig in the presence of mAbs against CD80 and bound to a 
B70/B7-2-transfected fibroblast cell line, demonstrating that the B70/B7-2 antigen is identical 
to CD86.  CD28 triggering was essential during D-Lc-induced alloreaction as it was inhibited 
by mAbs against CD28 (9 out of 11 tested). However, none of six anti-CDS0 mAbs demonstrated 
any activity on the D-I.c-induced aUoreaction, though some were previously described as inhibitory 
in assays using CD80-transfected cell lines.  In contrast, a mAb against CD86 (IT-2) was found 
to suppress  the D-Lc-dependent alloreaction by 70%.  This inhibitory effect was enhanced to 
i>90%  when a combination of anti-CD80 and anti-CD86 mAbs was used. The present results 
demonstrate that D-I.c express, in addition to CDS0, the other ligand for CTLA-4, CD86 (B70/B7- 
2), which plays a primordial role during D-Lc-induced alloreaction. 
1A though presentation of antigen to TCR is necessary for 
the initiation of T cell activation, costimulatory signals 
delivered by the APC permit a full immune response. The 
CD28 pathway is regarded as an essential costimulus of T 
cell activation (1). The coligation of the T cell CD28 receptors 
by the APC counter-receptors CD80  (B7/BB1)  or the re- 
cently identified B70/B7-2 (2-5) results in IL-2 production 
and T  cell proliferation (1,  2,  5). 
B70/B7-2 is expressed on resting monocytes and activated 
B and T cells and is upregulated on monocytes upon activa- 
tion (2-6). B7/BB1 and B70 expression on B ceils is upregu- 
lated by cross-linking MHC class II molecules (7), surface 
membrane Ig (6), or CD40 antigen (2, 8) and cytokines such 
as IL-2 and IL-4 (9). In vivo, blocking of the CD28/CTLA4 
pathway results in T cell anergy, prolongation of graft sur- 
vival,  and blocking of B cell responses (10-12). 
Dendritic cells (DC 1) comprise a system of highly efficient 
1 Abbreviations used in this paper: DC, dendritic cell; D-Lc, dendritic/ 
Langerhans cell. 
APC that function to initiate immune responses (13). In vivo, 
DC are involved in alloreactive T  cell activation as occurs 
during transplant rejection, and in vitro, primary alloreac- 
tive T  cell activation appears  to be essentially mediated by 
DC (14). Dendritic/Langerhans cells (D-Lc), generated by 
culturing human hematopoietic progenitor cells with GM- 
CSF and TNF-a, can induce strong proliferation of allogeneic 
T cells (15).  The present study was designed to investigate 
the expression and the function of CD28 counter-receptors 
on those in vitro-generated D-Lc. D-Lc were found to ex- 
press both B7/BB1 and B70, the latter being identical to the 
recently clustered B cell antigen CD86. Importantly, this study 
also concluded that B70/CD86  is the crucial CD28 ligand 
involved in D-Lc-induced T  cell alloreaction. 
Materials and Methods 
Hematopoietic  Factors, Reagents,  and Antibodies 
rhGM-CSF (sp act, 2  x  106 U/rag; Schering-Plough Research 
Institute, Kenilworth,  NJ) was used at 100 ng/ml, rhTNF-c~ (sp 
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at 2.5 ng/ml (16). rhlL-2 (sp act, 3  x  106 U/rag; Amgen, Thou- 
sand Oaks, CA) was used at 10 U/ml. PHA (Murex Diagnostics, 
Dartford, England) was used at 0.1/~g/ml. Anti-CDla mAbs used 
were OKT6-FITC (Ortho, Raritan, NJ) and DMC1 (provided by 
Dr. C. Dezutter-Dambuyant, INSERM U346, Lyon, France). Anti- 
CD80 mAbs included L307 and L308 (from Dr. L. Lanier, DNAX 
Research Institute) (17, 18), and mAb 104 (9). Anti-B70 mAb (IT-2) 
was generated by Dr. M. Azuma (2). Anti-CD28 mAb IOT28 was 
purchased from Immunotech (Marseille,  France).  The control fu- 
sion protein murine IL-4 receptor-Ig (mlL4R-Ig) was prepared as 
described (19). The following reagents were obtained through the 
V International Workshop on Human Leukocyte Differentiation 
Antigens (Boston, MA, 3-7 November 1993):  anti-CDf0,  anti- 
CD28,  anti-CD86  (FUN-1  and  BU63)  mAbs  and  the  human 
CTLA-4 human Ig fusion protein (CTLA4-Ig; from Dr. P. S. Linsley 
Oncogen,  Seattle,  WA). 
Collection  and Purification  of Cord Blood CD34 + Cells 
and Adult Blood  T  Cells 
CD34 § Cells.  Umbilical cord blood samples were obtained ac- 
cording to institutional  guidelines.  Cells bearing CD34 antigen 
were isolated from nonadherent mononuclear fractions through posi- 
tive selection by indirect immune "panning" using anti-CD34 mAb 
(Imu-133.3;  Immunotech).  A  second purification  step was per- 
formed using a cocktail of mAbs, as described (20).  Thus, in all 
experiments,  isolated cells  were 95-99%  CD34 +  as judged  by 
staining with anti-CD34  mAb. 
CD4 § T Cells.  Mononuclear cells, isolated from adult blood, 
were depleted of adherent  cells. CD4 § T  lymphocytes were purified 
by immunomagnetic depletion using a cocktail of mAbs IOM2 
(CD14),  ION16 (CD16), ION2 (HLA-DR) (Immunotech), NKH1 
(CD56), OKT8 (CD8) (Ortho), 4G7 (CD19), and mAb 89 (CD40). 
After two rounds of bead depletion, purity was routinely >95%. 
Cell  Cultures 
Generation of D-La  CD34 + cell  cultures  were established in 
the presence of GM-CSF and TNF-oe in medium consisting  of 
RPMI-1640 (GIBCO BILL, Gaithersburg, MD) supplemented with 
10% (vol/vol) FBS, 10 mM Hepes, 2 mM L-glutamine, 5  x  10 -s M 
2-# ME, penicillin (100 U/ml), and streptomycin (100/~g/ml) (re- 
ferred to as complete medium). CD34 + cells were seeded in 24-well 
culture plates at 2  x  104 cells/ml and cultures  were split every 
4-5 d.  After  12  d,  cultures  contained between 40  and 80%  of 
CDla + D-Lc (15) and cells were collected at that time point. 
T  Cell Proliferation Assay.  After 12 d of culture,  CD34 + he- 
matopoietic progenitor cells (HPC)-derived cells were collected and, 
after irradiation  (40 Gy), used as stimulator cells for resting allogeneic 
adult peripheral blood CD4 + T cells (2  x  104 per well).  10-3  x 
103  stimulator  cells  were  added  to  T  cells  in  96-well  round- 
bottomed tissue culture plates.  Control T  cell proliferation was 
performed using PHA (0.1/~g/ml) and IL-2 (10 U/ml). Except for 
kinetic experiments, cultures lasted 5 d. After incubation, cells were 
pulsed with  1/iCi  of [3H]TdR for the last 8 h,  harvested,  and 
counted. Tests were carried out in triplicate, and results were ex- 
pressed as cpm  _+  SD. 
Cytofluorimetric  Cell-surface  Phenotyping 
Double-color fluorescence was carried out by sequential incuba- 
tion of cells with unconjugated mAbs, PE-conjugated goat F(ab')2 
anti-mouse  Ig,  normal  mouse  sera,  and  FITC-coupled  OKT6 
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(CDla) (all from Ortho). For CTLA4-Ig fusion protein staining, 
as previously described (2),  cells were incubated with anti-CDf0 
mAbs (1.307, L308, or mAb 104), anti-B70 mAb (IT-2), anti-CD86 
(Fun-1  or  BU63),  unrelated  mAbs,  or combinations  of these. 
CTLA4-Ig  was  revealed  by  PE-conjugated  goat  F(ab')2 
anti-human IgG (Fc specific), absorbed on mouse Ig (Jackson Im- 
munoResearch Labs., Inc., West Grove, PA). Cells were then double 
stained with FITC-coupled OKT6 (CDla). Negative controls were 
performed with unrelated murine mAbs and mlL4R-Ig fusion pro- 
tein. Fluorescence was measured with a FACScan |  (Beeton Dick- 
inson & Co.,  Mountain  View,  CA). 
B70  Transfectants 
Human B70 eDNA (2) in the pBJ expression vector (21) was 
used to stably transfeet murine L cells expressing human CD32, 
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Figure  1.  In vitro-generated CDla + D-Lc express  CDS0 (B7/BB1), 
B70/B7-2, and CD86. D-Lc were labeled either with CTLA4-1g (A), anti- 
CD80 (L307, L308, and mAbl04 were used and L307 is shown) (B), anti- 
BT0 (IT-2)  (C),  anti-CD86  (FUN-I)  (E),  or anti-CO86  (BU63)  (F)  re- 
vealed by PE-conjugated goat anti-human Ig (A) or PE-conjugated goat 
anti-mouse Ig (/3, C, E, and F). Then, after saturation in 2% mouse serum, 
cells were stained by FITC-conjugated anti-CDla (OKT6).  In dot plot 
(D), cells were first labeled with anti-CD80  (L307)  revealed by FITC- 
conjugated goat anti-mouse Ig, saturated in 2% mouse serum and stained 
by hiotinylated anti-B70 (IT-2), revealed by PE-conjugated streptavidin. 
Quad limits were positioned on the negative control (data not shown). 
Results are representative of more than  10 mcperiments. 
Ligand for CD28  on Dendritic Cells as described (22). B70-transfected  L cells were selected for growth 
in I mg/ml G418 (Schering-Plough  Research Institute), and trans- 
fectants with the highest cell surface  density of  B70 expression were 
isolated by flow cytometry. 
Poesults 
In  Vitro-generated  CDla + D-Lc Bind CTLA4-Ig  through 
both B7/BB1  and B70/B7-2.  We wondered whether D-Ix 
generated in vitro by culturing CD34 + cells for 12 d with 
GM-CSF  +  TNF-ot (12-d D-Lc)  expressed  CD80 as well 
as B70/B7-2. As shown in Fig.  1 most CDla + D-IX bound 
CTLA4-Ig (Fig.  1 A) and expressed CDS0 at two different 
intensity levels (low and high) (Fig.  1 B). In contrast, only 
a  subset of CDla + D-IX expressed  B70/B7-2  (Fig.  1 C). 
Double staining with anti-CDS0 and anti-B70 mAbs showed 
that B70/B7-2 + cells comprised all CD80hig  h and that all 
B70/B7-2-  cells were CD80  l~  (Fig.  1 D). In 10 indepen- 
dent experiments, 90  _+  8%  (80-100%)  of CDla + D-IX 
were found to express CDS0 whereas only 55  _+ 20 (20-70%) 
expressed  B70/B7-2. 
As activated human B cells have been reported to express 
a third ligand for CD28/CTLA4 (6),  we searched for this 
structure on D-IX by evaluating the effects of anti-CD80 and 
anti-B70 mAbs on the binding of CTLA4-Ig. 12-d D-IX were 
first incubated with one anti-CD80 mAb (L307, L308, mAb 
104) or isotype control without or with the BT0-specific  mAb 
IT-2, and then labeled with CTLA4-Ig (or mlL4R-Ig), re- 
vealed by PE-conjugated anti-human IgG. Cells were finally 
stained with FITC anti-CDla mAb (or FITC IgG1 control). 
Fig. 2 A  shows that all CDla + ceils bound CTLA4-Ig and 
a subset (45-85%)  still bound CTLA4-Ig after incubation 
with any of the four anti-CD80 mAb (only L307 is shown). 
In the presence of anti-B70 mAb, all CDla + cells still bound 
CTLA4-Ig though with a slightly decreased intensity (50% 
decrease in mean fluorescence intensity (MFI)). However, in- 
cubation of CDla + cells with anti-B70 mAb and any anti- 
CD80 mAb totally prevented the binding of CTLA4-Ig (Fig. 
2 B), thus excluding the presence of a third CD28/CTLA4 
counterstructure. Taken together, these results demonstrate 
that in vitro-generated D-l.c express both CD80 and B70/B7-2 
which account for all CTLA4-Ig binding sites. 
B70/B7-2 Is Identical to CD86.  A phenotypic analysis of 
D-Lc with mAbs from the V  International Workshop on 
Human Leukocyte Differentiation Antigens indicated that 
mAbs against CD86  (FUN-1  and BU63)  stained CDla + 
D-Lc in a manner comparable to that of anti-B70 mAb (Fig. 
1, C, E, and F). In addition, kinetics studies  of B70/B7-2 
and CD86 expression  indicated that the two molecules ap- 
peared concommitantly during generation and maturation 
of D-l.c (data not shown). Furthermore, as previously shown 
for mAb IT-2, mAbs against CD86 (FUN-1 is shown) used 
alone induced a slight decrease in intensity of CTLA4-Ig 
binding (50% decrease in MFI) (Fig. 2 C), and combination 
of anti-CD86 and anti-CDS0 mAbs completely prevented 
the binding of CTLA4-Ig (Fig. 2 C). Finally, the anti-CD86 
mAbs (FUN-1 and BU63) bound to a B70-transfected L cell 
line but not to the control L cell line (Fig. 3). Taken together, 
these results demonstrate that B70/B7-2 is identical to CD86. 
CTLA 4-Ig Suppresses D-Lc-induced  Alloreaction Mainly by 
Blocking CD28/CD86 Interaction.  Since,  interactions between 
CD28/CTLA4 and their counter-receptors have been described 
as necessary for APC-dependent T cell activation, we inves- 
tigated whether blocking of these interactions would also 
inhibit a D-ix-induced T cell aUoreaction. First, the CTLA4-Ig 
fusion molecule was used to interfere with CD28/CD28 ligand 
interactions that may occur during the D-Ix-induced alloreac- 
tire CD4 + T cell proliferation. As shown in Fig. 4 A  (Exp. 
I), CTLA4-Ig inhibited D-Ix-induced alloreaction in a dose- 
dependent manner with half-maximal inhibition at 2.5/~g/ml 
and maximal inhibition at 10/~g/ml. At high numbers of 
D-Ix (3  x  103 D-Ix for 2  x  104 CD4 + T cells), CTLA4-Ig 
caused a 60% inhibition (45-70%, n =  6) ofT cell prolifer- 
ation (Fig.  4 B).  At lower D-IX concentrations (3  x  102 
D-IX),  CTLA4-Ig inhibited T  cell  proliferation by 85% 
(75-95%, n  =  6). A mlL4R-Ig fusion protein, included as 
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Figure  2.  CD80  and B70/B7-2 
expression  account  for all CTLA4-1g 
binding and B70/B7-2 is linked to 
CD86. Inhibition of CTLA4-1g 
binding on DL-C by anti-CDS0 
(L307), anti-B70 (IT-2), or anti- 
CD86 (FUN-l) mAbs was tested. 
D-Lc were  preincubated  in the pres- 
ence of: (A) Isotype  control [] or 
anti-CDS0 mAb D; (B) anti-B70 
mAb [] or anti-CD80 + anti-B70 
mAbs •;  and (C) anti-CD86 mAb 
[]  or  anti-CD80  +  anti-CD86 
mAbs [] before CTLA4-Ig + PE 
goat  anti-human  Ig  staining. 
Gating was then set on CDla  + 
(OKT6-FITC stained) cells. Anti- 
CTLA-Ig  staining  on anti-CDS0 + 
anti-B70 mAbs preincubated cells 
was identical  to mlL-4R-lg  staining 
(data not shown). Results  are rep- 
resentative of six experiments. 
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Figure  3.  B70/B7-2 is identical  to CD86.  Staining  with anti-CD80 
(L307 and mAbl04) (A),  anti-B70 (IT-2) (B),  anti-CD86 (FUN-I) (C), 
and anti-CD86 (BU63) (D) was performed on a murine L cell line (unfilled 
histograms) and  a murine L cell line stably  transfected  with B70 (filled 
histograms). 
a control, never significantly affected any of the assays (Fig. 
4 A, Exp.  1,  and Fig. 4 B). 
We then wondered whether a CD28-specific mAb (IOT28) 
would also suppress a D-Lc-mediated alloreaction (Fig.  4). 
Depending  on  the D-Lc  concentration,  IOT28  caused  a 
50-85%  inhibition (35-90%,  n  =  6) of T  cell DNA syn- 
thesis (Fig. 4 B). This inhibitory effect was dose dependent 
with half-maximal effect at 0.5/~g/ml and maximal effect 
at 2.5  #g/ml  (Fig.  4 A). 
It is interesting to note that the anti-CD80 mAb L307, 
which suppresses  the development of CD8 cell cytotoxicity 
against CD80-transfected target cells (17), failed to inhibit 
D-Lc-induced alloreaction even at concentrations as high as 
10 #g/ml  (Fig.  4, A  and B).  To further strengthen these 
findings, all anti-CD28 and anti-CD80 antibodies available 
from the V Workshop on Human Leukocyte Differentiation 
Antigens were tested for their ability to affect D-Lc-induced 
alloreaction  and  to  alter  PHA  +  IL-2-dependent  T  cell 
proliferation. As shown in Fig. 5, although able to bind to 
D-l_c (data not shown), none of the mAbs against CD80 
demonstrated any activity on D-Lc-induced aUoreaction (Fig. 
5,  left).  Furthermore,  these CD80-specific  antibodies  did 
not affect PHA  +  IL-2-induced T  cell proliferation (Fig. 
5, right). In contrast, the CTLA4-Ig and 9 out of 11 mAbs 
against CD28 were found to inhibit by 55-85%  the D-Lc- 
induced alloreaction. The CTLA4-Ig molecule has no effect 
on PHA  +  IL-2-dependent T  cell proliferation, whereas, 
in accordance with their known costimulatory effects, the 
anti-CD28 mAbs that demonstrated blocking effect on D-Lc- 
induced alloreaction, costimulated T cell proliferation (1.8-2.2 
fold enhancement) in the presence of PHA +  IL-2. All anti- 
CD28 mAbs bound to T cell clones (data not shown), sug- 
gesting that the two mAbs lacking activity (M-T281  and 
CD28.4) recognized epitope(s) not involved in ligand binding. 
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Figure  4.  D-Lc-induced  alloreaction  is  blocked  by 
CTLA4-Ig, anti-CD28,  and anti-CD86 mAb. D-l_c  were used 
after irradiation  (40 Gy) as stimulator  cells for T call prolifer- 
ation.  2  ￿  104 CD4 + T cells were seeded in the presence 
of either 12-3  x  103  stimulator  cells per  well in 96-wall 
round-bottomed tissue cuhure plates. CTLA4-1g fusion pro- 
tein and mAbs against CD80 (L307), CD86 (IT-2), and CD28 
(IOT28)  were  added  at  10  /~g/ml  for most  experiments. 
mIL4K-Ig fusion protein  and unrelated  IgG1 were used as 
controls at the same concentrations.  (A) The dose-dependent 
effects of mAbs and fusion proteins  on D-Lc (103/well)-in - 
duced T cell alloreaction.  The proliferation  was revealed by 
[3H]TdR incorporation  after 4 d of cuhure.  (/3) The effects 
of mAbs and fusion proteins on a dose-dependent  D-I.c-in- 
duced  alloreaction.  The  proliferation  was  revealed  by 
[3H]TdR incorporation  after 4 d of cuhure.  (C) The effects 
of mAbs and chimeric molecules (10 #g/ml) on the kinetics 
of D-Lc (103/well)-induced T ceil alloreaction. The prolifer- 
ation was revealed by [3H]TdR incorporation at the indicated 
time points. Results are representative of six experiments. SD 
were below 10%  of variation. 
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Figure 5.  None  of  the  anti- 
CDS0 mAb block D-Lc-induced al- 
loreaction.  Anti-CD80  and  anti- 
CD28  mAbs,  from  the  V  Inter- 
national  Workshop  on  Human 
Leukocyte Differentiation Antigens, 
were  tested  on  D-Lc  (103/well; 
left)- and on PHA+I/r  (rigkt)-de- 
pendent  T  cell proliferation  (2  x 
104/well). All mAbs and chimeric 
molecules were tested at 10 #g/ml 
including controls.  Each bar repre- 
sents individual mAb except B7-G 
corresponding  to a combination of 
anti-CD80.  Proliferation  was  re- 
vealed by [3H]TdR incorporation at 
day 4. The results are representative 
of  three  experiments.  SD  were 
below 10%  of variation. 
Control isotype-matched mAbs did not significantly affect 
assays (Fig.  5). In contrast,  the anti-CD86  mAb IT-2 sup- 
pressed D-Lc-dependent  alloreaction  (60-80%,  n  =  3) by 
70%.  The inhibitory effect was dose-dependent with half- 
maximal effect at 0.5/xg/ml and maximal effect at 2.5/zg/ml 
(Fig. 4 A, Exp. 2). In addition, a combination of anti-CD80 
and anti-CD86 mAbs induced a nearly complete inhibition 
of T cell proliferation (88-100%, n  =  6), even at high D-Lc 
numbers  (data not  shown). 
The suppressive effect of CTLA4-Ig (data not shown), anti- 
CD28,  and anti-CD86  mAbs could be detected as early as 
after 2 d of cocuhure and was maintained  throughout  the 
culture period (Fig.  4 C). The blocking effect of CTLA4-Ig 
and anti-CD86 mAb was specific for the D-Lc-induced al- 
loreaction as they had no influence on PHA  +  IL-2-medi- 
ated T  cell proliferation at any concentration or at any time 
tested (data not shown). Taken together, those results dem- 
onstrate that CD28 triggering is crucial during D-Lc-induced 
alloreaction, and occurs primarily through CD86 and secon- 
darily through  CD80 interactions. 
Discussion 
The present study was designed to determine the expres- 
sion of the CD80 (B7/BB1) and B70/B7-2 accessory mole- 
cules on CD34 + progenitor-derived D-Lc and their contri- 
bution during D-Lc-induced T cell alloreactive proliferation. 
Using specific mAbs, CD80 was found to be expressed on 
virtually all CDla + D-Lc whereas B70/B7-2 expression was 
restricted  to  a  smaller  subset of CDla + D-Lc (50-70%). 
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This study also demonstrates formally the identity of B70/B7-2 
with CD86, a newly clustered antigen initially identified as 
a B cell activation antigen with the FUN-1 (23) and BU63 
mAbs. Functional studies demonstrated that CD28 triggering 
was a crucial event during  D-Lc-mediated T  cell alloreac- 
tion, a finding consistent with previous reports (24-26). The 
present  results  further  showed  B70/CD86  as  the  major 
counter-receptor involved in CD28 triggering as a mAb against 
B70/B7-2 (IT-2) blocks by 50-80% the D-L-induced T cell 
aUoreaction whereas none of the nine tested anti-CD80 mAbs 
directly affect such a biological function.  Yet,  CDS0 does 
play a secondary role as a combination of anti-CD86 and anti- 
CD80 mAbs results in a complete abrogation of T cell acti- 
vation. Such a finding suggests that no other accessory mol- 
ecule, e.g., a third CD28 ligand (4, 6), can replace these known 
CD28 ligands. Indeed, phenotypic analysis indicated that all 
CTLA4-Ig ligands on CDla + D-Lc were accounted for by 
CD80 and CD86 as a combination of mAbs directed against 
these two antigens completely inhibited the binding of the 
CTLA4-Ig fusion protein. Furthermore, although CD80 and 
CD86 antigens are upregulated on D-I.x: during CD40 trig- 
gering,  a third CTLA4/CD28 counter-structure  could not 
be detected after such activation  (27). 
The rationale for expression of two (or more) molecules 
mediating apparently similar effects on T  cell activation is 
currently unknown.  However, differences in the kinetics of 
upregulation  during  B cell activation  (4,  6),  as well as its 
restricted expression on germinal center B cells (23) may argue 
for specific roles of CD86 versus CD80. During maturation 
of CD34 +-derived D-l.c,  CD80 appears earlier than CD86 
(data  not  shown)  and expression of CD86  delineates two subsets among CDla § D-Lc (CD80 +, CD86 + and CD80 +, 
CD86-) which might represent different maturation or ac- 
tivation stages of D-l.c. In addition, CD86 is more strongly 
upregulated than CD80 during CD40 activation of CDla + 
D-l_c (27). Such differential kinetics of  expression during matu- 
ration and activation might suggest specific roles for CD80 
versus  CD86 during a T  cell immune response. 
The identification of CD86 is the major ligand for CD28 
expressed  on dendritic cells, will enable further manipula- 
tion of the CD28 pathway, potentially leading to a therapeutic 
strategy for the control of autoimmunity or transplantation 
tolerance. The importance of the CD28 counter-receptors in 
tumor immunity (28, 29) and the fact that D-Lc express spon- 
taneously high levels of CD80 and CD86 antigens, represent 
new arguments to consider these in vitro generated D-Lc as 
an interesting material for development of immunotherapy 
strategies  using tumor-associated antigens. 
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